<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942160</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-202</org_study_id>
    <nct_id>NCT02942160</nct_id>
  </id_info>
  <brief_title>EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)</brief_title>
  <official_title>A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic
      Panniculopathy (commonly known as Cellulite).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2016</start_date>
  <completion_date type="Actual">June 14, 2018</completion_date>
  <primary_completion_date type="Actual">June 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary cellulite severity endpoint defined as proportion of composite responders at day 71</measure>
    <time_frame>Day 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of composite responders defined as subjects with an improvement in severity in the CR-PCSS (Clinician-Reported Photonumeric Cellulite Severity Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of composite responders defined as subjects with an improvement in severity in the PR-PCSS (Patient-Reported Photonumeric Cellulite Severity Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at each level of improvement in the PR-PCSS (Patient-Reported Photonumeric Cellulite Severity Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at each level of improvement in the CR-PCSS (Clinician-Reported Photonumeric Cellulite Severity Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with a response of 1 or better in the I-GAIS (Investigator-Global Aesthetic Improvement Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders with a response of 1 or better in the S-GAIS (Subject-Global Aesthetic Improvement Scale)</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at each level of the subject satisfaction with cellulite treatment</measure>
    <time_frame>Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hexsel CSS total score</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>EN3835 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EN3835 0.84mg (Collagenase Clostridium Histolyticum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collagenase Clostridium Histolyticum</intervention_name>
    <arm_group_label>EN3835 Active</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Observation Phase:

          -  Voluntarily sign and date an informed consent agreement

          -  Have participated in and completed the double-blind study EN3835-201

          -  Be willing to apply sunscreen to any treated quadrant before each exposure to sun

        Inclusion Criteria for Treatment Phase:

          -  Voluntarily sign and date an informed consent agreement

          -  Have participated in and completed the double-blind study EN3835-201

          -  Be willing to apply sunscreen to any treated quadrant before each exposure to sun

          -  Have at least 1 quadrant with: a score of 3 or 4 (moderate or severe) as reported on
             the PCSS (Photonumeric Cellulite Severity Scale) by the subject or investigator, and a
             Hexsel CSS (Cellulite Severity Scale) score no greater than 13

          -  Be judged to be in good health

          -  Have a negative urine pregnancy test at screening and be using an effective
             contraception method, be surgically sterile, or post-menopausal

        Exclusion Criteria for Observation Phase:

          -  None

        Exclusion Criteria for Treatment Phase:

          -  Has used, or intends to use during the course of the study, other treatment of EFP on
             the legs or buttocks

          -  Is presently nursing a baby or providing breast milk for a baby

          -  Intends to become pregnant during the study

          -  Currently receiving, has received within 7 days before injection of study drug, or
             plans to receive an anticoagulant or antiplatelet medication

          -  History of stroke or bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike McLane</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #4</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #5</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #6</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #7</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #8</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #10</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #9</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #11</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #12</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #13</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #14</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #15</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <disposition_first_submitted>June 12, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 12, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 14, 2019</disposition_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

